Skip to content
Open access

D‐Psicose Attenuates Hepatic Steatosis and Inflammatory Injury in HFD/STZ‐Induced T2DM Mice and Is Associated With Alterations in Gut Microbiota, Tryptophan Metabolism, and Hepatic AhR‐Related Signaling

Oct 2026 · Food Science & Nutrition · Vol 14 · 0 citations · 42 references
Medicine

TL;DR

DPS improved metabolic and liver‐related abnormalities in diabetic mice and was accompanied by coordinated changes in intestinal barrier‐related indices, gut microbial composition, tryptophan metabolites, and hepatic AhR/NF‐κB‐related markers, which do not demonstrate a causal gut microbiota–tryptophan–AhR mechanism.

Abstract

ABSTRACT D‐psicose (DPS) is a rare sugar with reported metabolic benefits, but its effects on diabetes‐associated liver abnormalities and related gut–liver changes remain insufficiently defined. Here, DPS was evaluated in mice with Type 2 diabetes mellitus induced by a high‐fat diet and streptozotocin. Low‐ and high‐dose DPS interventions were assessed through serum biochemistry, liver histology, inflammatory cytokine measurements, intestinal barrier evaluation, hepatic molecular analysis, 16S rRNA gene sequencing, targeted quantification of tryptophan metabolites, and untargeted serum metabolomics. Relative to untreated diabetic mice, DPS‐treated animals showed improved serum lipid profiles, lower ALT and AST activities, reduced circulating inflammatory cytokines, and less hepatic lipid deposition. DPS treatment was also accompanied by improved intestinal morphology, increased ZO‐1 and Occludin expression, and lower circulating lipopolysaccharide concentrations. In the high‐dose group, gut microbial community composition differed from that of untreated diabetic mice, with relative increases in Akkermansia and Lactobacillus. In parallel, DPS treatment was associated with increased serum tryptophan and indole‐3‐propionic acid concentrations, lower kynurenine concentrations and Kyn/Trp ratios, reduced hepatic TDO2 expression, increased AhR expression, and lower NF‐κB p65 phosphorylation. Overall, DPS improved metabolic and liver‐related abnormalities in diabetic mice and was accompanied by coordinated changes in intestinal barrier‐related indices, gut microbial composition, tryptophan metabolites, and hepatic AhR/NF‐κB‐related markers. As microbiota‐directed and AhR‐targeted intervention experiments were not conducted, these observations remain associative and do not demonstrate a causal gut microbiota–tryptophan–AhR mechanism. Moreover, as these observations were obtained in a single HFD/STZ‐induced mouse model, their relevance to the heterogeneity and natural course of human T2DM‐associated MASLD requires confirmation in additional preclinical models and clinical studies.

Read PDF

Similar papers

Oct 2026

Combination of Empagliflozin and Resveratrol Mitigates Hepatic Steatosis via Attenuation of Inflammation and Promotion of Adipose Tissue Browning in High‐Fat Diet‐Fed C57BL/6J Mice

The combined effects of empagliflozin and resveratrol treatment on obesity‐associated MASLD in a high‐fat diet (HFD)‐fed mouse model reduced body weight gain and improved glucose tolerance more effectively than monotherapies.

A. Soleimani, Masoume Aliabadi, Jamal Amri et al. · 0 citations
Open access Oct 2026

Macrostemonoside I alleviates metabolic dysfunction-associated steatotic liver disease in mice: potential involvement of SCAP/SREBP2 signaling in cholesterol metabolism

The progression of metabolic dysfunction-associated steatotic liver disease (MASLD) involves lipotoxicity and inflammation from disordered cholesterol metabolism. Macrostemonoside I (MI), an Allium saponin monomer, may regulate cholesterol metabolism, but its role in MASLD is unclear. MASLD was induced...

Ji-Yuan Su, Shou-Yu Lin, Chuan-Shen Jiang et al. · 0 citations
Open access Sep 2026

Furong Tongmai Capsule Ameliorates Atherosclerosis in ApoE −/− Mice by Modulating Gut Microbiota, Arachidonic Acid Metabolism and Macrophage Polarization

ABSTRACT Furong Tongmai capsule (FRTM) is a traditional Chinese medicine formula with reported lipid‐lowering and anti‐inflammatory activities, but its mechanisms in atherosclerosis (AS) remain unclear. In ApoE−/− mice fed a high‐fat diet, FRTM administration improved serum lipid profiles by reducing total cholesterol,...

Shu-Quan Lv, Han-Zhou Li, Yu-Ming Wang et al. · 0 citations
Open access Sep 2026

Dietary alpha-lipoic acid supplementation alleviates high-fat diet-induced hepatic steatosis and inflammation by remodeling the gut microbiota and restoring the primary bile acid pool.

Findings elucidate a novel 'gut microbiota-primary bile acid' axis underlying the hepatoprotective effects of dietary ALA, supporting its potential as a functional food component or dietary supplement for MASLD management.

Peng-Fei Ren, Hui Qi, Bi-Qian Wei et al. · 0 citations
Open access Oct 2026

Compound probiotics mitigate alcohol-induced liver injury in mice by regulating the gut microbiota and TLR4/NF-κB pathway

Alcohol-related liver disease (ALD) is a worldwide disorder with limited treatment options. As a result, probiotics are emerging as a potential complementary therapy. This research investigated the efficacy of the compound probiotics (Bifidobacterium animalis subsp. lactis GOLDGUT-BB18 and Lactobacillus acidophilus...

Patthanan Sakda, Jun Wang, Tian Liu et al. · 0 citations
Open access Sep 2026

Effects of Lactobacillus acidophilus on hepatic and microbial dysregulation in MASLD and diabetes

Findings suggest that L. acidophilus may improve metabolic dysfunction through coordinated hepatic metabolic regulation and gut microbial modulation, supporting its potential as a probiotic candidate for MASLD and diabetes-associated metabolic disease.

H. Park, In-gyu Park, Jeong Ha Park et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.